hVIVO PLC
22 September 2026
hVIVO plc
(“hVIVO”, the “Company" or the “Group”)
Board Changes
London, UK – 22 September 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, today announces the following changes to the Board as part of the ongoing evolution of its composition.
-Appointment of Caroline Shaw, CBE as Independent Non-Executive Director, effective from 1 October 2026. Caroline will also serve as Chair of the Remuneration Committee and as a member of the Audit Committee
-Elaine Sullivan to step down as Independent Non-Executive Director, effective from 1 October 2026
Appointment of Caroline Shaw, CBE: Caroline brings more than 30 years’ senior healthcare leadership experience across the NHS, independent healthcare, digital health and life sciences. She has held Chief Executive and board-level roles in both the public and private sectors, with expertise spanning strategy, clinical governance, operational transformation and commercial growth.
Her prior roles include Chief Executive Officer of Evergreen Life where she led a successful turnaround to profitability; Chief Executive Officer of Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust; Chief Operating Officer / Deputy Chief Executive Officer of Nottingham University Hospitals NHS Trust; and Chief Executive Officer of The Christie NHS Foundation Trust.
Resignation of Elaine Sullivan: Concurrently, Elaine Sullivan will step down as an independent Non-Executive Director. Elaine joined the Board of hVIVO (then part of Open Orphan) in November 2020 and has previously served as Senior Independent Director and Chair of the Remuneration Committee.
Shaun Chilton, Non-Executive Chair of hVIVO plc, said: “On behalf of the Board, I would like to thank Elaine for her contribution to hVIVO over the past six years during a period of strategic transformation. We wish her every success for the future.
"We are delighted to welcome Caroline Shaw to the Board.Her extensive clinical, operational and commercial leadership experience will be valuable as we continue to develop hVIVO’s broader, integrated clinical development platform and realise the significant opportunities it has to offer.”
Additional Information on the Board Appointment
The following additional information is provided with regards to the appointment of Caroline Sarah Shaw, aged 59, in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
|
Current directorships/partnerships: |
Former directorships/partnerships (within the last five years): |
|
None |
Evergreen Health Solutions Ltd |
|
|
Omnes Group Ltd |
|
|
Omnes Healthcare Ltd |
|
|
Queen Elizabeth Hospital King's Lynn NHS Foundation (Trust) |
Caroline Shaw does not hold any shares or options in the Company. There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
For further information please contact:
|
hVIVO plc |
+44 (0)20 7756 1300 | |||
|
Yamin ‘Mo’ Khan, Chief Executive Officer Susan Stuart, Head of IR and Corporate Communications |
| |||
|
|
| |||
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) |
+44 (0)20 7220 0500 | |||
|
Geoff Nash, Callum Davidson, Nigel Birks |
| |||
|
|
| |||
|
Peel Hunt LLP (Joint Broker) |
+44 (0)20 7418 8900 | |||
|
James Steel, Dr Christopher Golden |
| |||
|
|
| |||
|
Davy (Joint Broker) |
+353 (0) 1 679 6363 | |||
|
Anthony Farrell, Niall Gilchrist |
| |||
|
|
| |||
|
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson
|
hVIVO@icrhealthcare.com | |||
Notes to Editors
About hVIVO
hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.
The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.
With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.
- Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.
- Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.
- Human Challenge Trials leverages hVIVO’s state-of-the-art quarantine facility in London – the largest of its kind worldwide – to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.
- Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.